Micro-NMR for rapid molecular analysis of human tumor samples

Science Translational Medicine

Volumn 3, Issue 71, 2011, Pages

  Haun, Jered B ^a   Castro, Cesar M ^a,b   Wang, Rui ^a,c   Peterson, Vanessa M ^a,d   Marinelli, Brett S ^a   Lee, Hakho ^a   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; KI 67 ANTIGEN; MUCIN 1; NANOPARTICLE; PROTEIN B7 H3; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

ABDOMINAL CANCER; ABDOMINAL TUMOR; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MAGNETIC FIELD; MALE; MICRO NUCLEAR MAGNETIC RESONANCE; MOBILE PHONE; NUCLEAR MAGNETIC RESONANCE; PORTABLE EQUIPMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMART PHONE; STOMACH BIOPSY; VALIDATION PROCESS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952204045     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002048     Document Type: Article

References (55)

1. S. Ramaswamy, K. N. Ross, E. S. Lander, T. R. Golub, A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54 (2003).
2. B. S. Taylor, S. Varambally, A. M. Chinnaiyan, A systems approach to model metastatic progression. Cancer Res. 66, 5537-5539 (2006).
3. S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R. G. Tompkins, T. J. Lynch, M. Toner, D. A. Haber, Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).
4. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000).
5. S. L. Spencer, S. Gaudet, J. G. Albeck, J. M. Burke, P. K. Sorger, Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459, 428-432 (2009).
6. D. D. Von Hoff, J. J. Stephenson Jr., P. Rosen, D. M. Loesch, M. J. Borad, S. Anthony, G. Jameson, S. Brown, N. Cantafio, D. A. Richards, T. R. Fitch, E. Wasserman, C. Fernandez, S. Green, W. Sutherland, M. Bittner, A. Alarcon, D. Mallery, R. Penny, Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877-4883 (2010).
7. D. J. Brennan, D. P. O'Connor, E. Rexhepaj, F. Ponten, W. M. Gallagher, Antibody-based proteomics: Fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 10, 605-617 (2010).
8. W. Bruening, J. Fontanarosa, K. Tipton, J. R. Treadwell, J. Launders, K. Schoelles, Systematic review: Comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann. Intern. Med. 152, 238-246 (2010).
9. R. C. Bast Jr., H. Lilja, N. Urban, D. L. Rimm, H. Fritsche, J. Gray, R. Veltri, G. Klee, A. Allen, N. Kim, S. Gutman, M. A. Rubin, A. Hruszkewycz, Translational crossroads for biomarkers. Clin. Cancer Res. 11, 6103-6108 (2005).
10. K. L. Bolton, M. Garcia-Closas, R. M. Pfeiffer, M. A. Duggan, W. J. Howat, S. M. Hewitt, X. R. Yang, R. Cornelison, S. L. Anzick, P. Meltzer, S. Davis, P. Lenz, J. D. Figueroa, P. D. Pharoah, M. E. Sherman, Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol. Biomarkers Prev. 19, 992-999 (2010).
11. R. G. Sheiman, C. Fey, M. McNicholas, V. Raptopoulos, Possible causes of inconclusive results on CT-guided thoracic and abdominal core biopsies. AJR Am. J. Roentgenol. 170, 1603-1607 (1998).
12. P. R. Mueller, E. vanSonnenberg, Interventional radiology in the chest and abdomen. N. Engl. J. Med. 322, 1364-1374 (1990).
13. R. Weissleder, A. Moore, U. Mahmood, R. Bhorade, H. Benveniste, E. A. Chiocca, J. P. Basilion, In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6, 351-355 (2000).
14. R. Weissleder, M. J. Pittet, Imaging in the era of molecular oncology. Nature 452, 580-589 (2008).
15. H. Lee, E. Sun, D. Ham, R. Weissleder, Chip-NMR biosensor for detection and molecular analysis of cells. Nat. Med. 14, 869-874 (2008).
16. J. M. Perez, L. Josephson, T. O'Loughlin, D. Högemann, R. Weissleder, Magnetic relaxation switches capable of sensing molecular interactions. Nat. Biotechnol. 20, 816-820 (2002).
17. H. Lee, T. J. Yoon, J. L. Figueiredo, F. K. Swirski, R. Weissleder, Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc. Natl. Acad. Sci. U.S.A. 106, 12459-12464 (2009).
18. E. Durr, J. Yu, K. M. Krasinska, L. A. Carver, J. R. Yates, J. E. Testa, P. Oh, J. E. Schnitzer, Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat. Biotechnol. 22, 985-992 (2004).
19. S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber, M. Toner, Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239 (2007).
20. L. V. Sequist, S. Nagrath, M. Toner, D. A. Haber, T. J. Lynch, The CTC-chip: An exciting new tool to detect circulating tumor cells in lung cancer patients. J. Thorac. Oncol. 4, 281-283 (2009).
21. S. B. Ho, G. A. Niehans, C. Lyftogt, P. S. Yan, D. L. Cherwitz, E. T. Gum, R. Dahiya, Y. S. Kim, Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53, 641-651 (1993).
22. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, M. Press, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
23. T. J. Roth, Y. Sheinin, C. M. Lohse, S. M. Kuntz, X. Frigola, B. A. Inman, A. E. Krambeck, M. E. McKenney, R. J. Karnes, M. L. Blute, J. C. Cheville, T. J. Sebo, E. D. Kwon, B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900 (2007).
24. J. B. Haun, N. K. Devaraj, S. A. Hilderbrand, H. Lee, R. Weissleder, Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat. Nanotechnol. 5, 660-665 (2010).
25. S. L. Stott, R. J. Lee, S. Nagrath, M. Yu, D. T. Miyamoto, L. Ulkus, E. J. Inserra, M. Ulman, S. Springer, Z. Nakamura, A. L. Moore, D. I. Tsukrov, M. E. Kempner, D. M. Dahl, C. L. Wu, A. J. Iafrate, M. R. Smith, R. G. Tompkins, L. V. Sequist, M. Toner, D. A. Haber, S. Maheswaran, Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2, 25ra23 (2010).
26. H. Mischak, G. Allmaier, R. Apweiler, T. Attwood, M. Baumann, A. Benigni, S. E. Bennett, R. Bischoff, E. Bongcam-Rudloff, G. Capasso, J. J. Coon, P. D'Haese, A. F. Dominiczak, M. Dakna, H. Dihazi, J. H. Ehrich, P. Fernandez-Llama, D. Fliser, J. Frokiaer, J. Garin, M. Girolami, W. S. Hancock, M. Haubitz, D. Hochstrasser, R. R. Holman, J. P. Ioannidis, J. Jankowski, B. A. Julian, J. B. Klein, W. Kolch, T. Luider, Z. Massy, W. B. Mattes, F. Molina, B. Monsarrat, J. Novak, K. Peter, P. Rossing, M. Sánchez-Carbayo, J. P. Schanstra, O. J. Semmes, G. Spasovski, D. Theodorescu, V. Thongboonkerd, R. Vanholder, T. D. Veenstra, E. Weissinger, T. Yamamoto, A. Vlahou, Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2, 46ps42 (2010).
27. A. Saadi, N. B. Shannon, P. Lao-Sirieix, M. O'Donovan, E. Walker, N. J. Clemons, J. S. Hardwick, C. Zhang, M. Das, V. Save, M. Novelli, F. Balkwill, R. C. Fitzgerald, Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc. Natl. Acad. Sci. U.S.A. 107, 2177-2182 (2010).
28. M. Cristofanilli, V. Valero, A. U. Buzdar, S. W. Kau, K. R. Broglio, A. M. Gonzalez-Angulo, N. Sneige, R. Islam, N. T. Ueno, T. A. Buchholz, S. E. Singletary, G. N. Hortobagyi, Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 110, 1436-1444 (2007).
29. N. Erez, M. Truitt, P. Olson, S. T. Arron, D. Hanahan, Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 17, 135-147 (2010).
30. R. Kalluri, R. A. Weinberg, The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
31. G. Lahat, Q. S. Zhu, K. L. Huang, S. Wang, S. Bolshakov, J. Liu, K. Torres, R. R. Langley, A. J. Lazar, M. C. Hung, D. Lev, Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 5, e10105 (2010).
32. C. J. Creighton, X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, D. L. Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, C. Fan, X. Zhang, X. He, A. Pavlick, M. C. Gutierrez, L. Renshaw, A. A. Larionov, D. Faratian, S. G. Hilsenbeck, C. M. Perou, M. T. Lewis, J. M. Rosen, J. C. Chang, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U.S.A. 106, 13820-13825 (2009).
33. M. S. Tsao, A. Sakurada, J. C. Cutz, C. Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, P. Marrano, G. da Cunha Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F. A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
34. D. S. Tan, G. V. Thomas, M. D. Garrett, U. Banerji, J. S. de Bono, S. B. Kaye, P. Workman, Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer J. 15, 406-420 (2009).
35. R. A. Betensky, D. N. Louis, J. G. Cairncross, Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20, 2495-2499 (2002).
36. Y. Liu, H. Wang, Nanomedicine: Nanotechnology tackles tumours. Nat. Nanotechnol. 2, 20-21 (2007).
37. D. A. Giljohann, C. A. Mirkin, Drivers of biodiagnostic development. Nature 462, 461-464 (2009).
38. J. Alper, US NCI launches nanotechnology plan. Nat. Biotechnol. 22, 1335-1336 (2004).
39. M. Ferrari, Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
40. O. C. Farokhzad, R. Langer, Impact of nanotechnology on drug delivery. ACS Nano 3, 16-20 (2009).
41. C. S. Thaxton, R. Elghanian, A. D. Thomas, S. I. Stoeva, J. S. Lee, N. D. Smith, A. J. Schaeffer, H. Klocker, W. Horninger, G. Bartsch, C. A. Mirkin, Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc. Natl. Acad. Sci. U.S.A. 106, 18437-18442 (2009).
42. J. Sun, M. D. Masterman-Smith, N. A. Graham, J. Jiao, J. Mottahedeh, D. R. Laks, M. Ohashi, J. DeJesus, K. Kamei, K. B. Lee, H. Wang, Z. T. Yu, Y. T. Lu, S. Hou, K. Li, M. Liu, N. Zhang, S. Wang, B. Angenieux, E. Panosyan, E. R. Samuels, J. Park, D. Williams, V. Konkankit, D. Nathanson, R. M. van Dam, M. E. Phelps, H.Wu, L. M. Liau, P. S. Mischel, J. A. Lazareff, H. I. Kornblum, W. H. Yong, T. G. Graeber, H. R. Tseng, A microfluidic platform for systems pathology: Multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res. 70, 6128-6138 (2010).
43. Y. Komohara, J. Hirahara, T. Horikawa, K. Kawamura, E. Kiyota, N. Sakashita, N. Araki, M. Takeya, AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J. Histochem. Cytochem. 54, 763-771 (2006).
44. A. Leimgruber, C. Berger, V. Cortez-Retamozo, M. Etzrodt, A. P. Newton, P. Waterman, J. L. Figueiredo, R. H. Kohler, N. Elpek, T. R.Mempel, F. K. Swirski, M. Nahrendorf, R. Weissleder, M. J. Pittet, Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia 11, 459-468 (2009).
45. F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J. L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E. Aikawa, T. R. Mempel, P. Libby, R. Weissleder, M. J. Pittet, Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616 (2009).
46. M. Wildgruber, H. Lee, A. Chudnovskiy, T. J. Yoon, M. Etzrodt, M. J. Pittet, M. Nahrendorf, K. Croce, P. Libby, R. Weissleder, F. K. Swirski, Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One 4, e5663 (2009).
47. J. Y. Pierga, F. C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. de Cremoux, R. Salmon, A. Vincent-Salomon, M. Marty, Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 14, 7004-7010 (2008).
48. J. Kaiser, Medicine. Cancer's circulation problem. Science 327, 1072-1074 (2010).
49. S. Hanash, A. Taguchi, The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 10, 652-660 (2010).
50. T. D'Alfonso, Y. F. Liu, S. Monni, P. P. Rosen, S. J. Shin, Accurately assessing HER-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: Emerging questions and considerations addressed. Am. J. Surg. Pathol. 34, 575-581 (2010).
51. A. Khan, M. S. Sabel, A. Nees, K. M. Diehl, V. M. Cimmino, C. G. Kleer, A. F. Schott, D. F. Hayes, A. E. Chang, L. A. Newman, Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann. Surg. Oncol. 12, 697-704 (2005).
52. A. Makris, T. J. Powles, D. C. Allred, S. E. Ashley, P. A. Trott, M. G. Ormerod, J. C. Titley, M. Dowsett, Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Res. Treat. 53, 51-59 (1999).
53. N. K. Devaraj, R. Upadhyay, J. B. Haun, S. A. Hilderbrand, R. Weissleder, Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew. Chem. Int. Ed. Engl. 48, 7013-7016 (2009).
54. F. Reynolds, T. O'loughlin, R. Weissleder, L. Josephson, Method of determining nanoparticle core weight. Anal. Chem. 77, 814-817 (2005).
55. Acknowledgments: We thank A. Guimaraes for assistance with the initial IRB protocol, A. Thabet and B. Pomerantz for sample collection, D. Issadore for helping perform μNMR measurements, C. Min for developing the smart phone interface, N. Devaraj and S. Hilderbrand for synthesizing chemical reagents, and Y. Fisher-Jeffes for manuscript review. We also thank M. Pittet and F. Swirski for their many helpful discussions and for data review. Finally, we are grateful to M. Toner and D. Haber for their invaluable insight and suggestions. Funding: Supported in part by NIH grants (RO1 EB004626, RO1 EB010011, U54 CA119349, UO1 HL080731, P50 CA127003, T32 CA079443, and F32 CA144139). Author contributions: J.B.H., C.M.C., H.L., and R. Weissleder designed the research; J.B.H., V.M.P., B.S.M., and H.L. performed the research; J.B.H., C.M.C., R. Wang, H.L., and R. Weissleder analyzed the research; and J.B.H., C.M.C., H.L., and R. Weissleder wrote the paper. Competing interests: The authors declare that they have no competing interests.